Neuralstem possesses patented technology that enables the production of neural stem cells of the human brain and spinal cord in commercial quantities, as well as the ability to control the differentiation of these cells into mature, physiologically relevant human neurons and glia. The company has been awarded orphan status designation by the FDA for its amyotrophic lateral sclerosis (ALS) cell therapy. Neuralstem also has product candidates currently undergoing trials. For more information, visit the company’s Web site at www.neuralstem.com.

The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded biotech companies. Each year the annual event provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. For more information on Biotechnology Industry Organization (BIO), visit www.bio.org.

Let us hear your thoughts below: